PRECLINICAL EXPERIMENTAL SCREENING MODELS FOR THE ASSESSMENT OF ANTI-CANCER DRUGSAbstract
Cancer, according to WHO, is a generic terminology for a group of diseases that are characterized by abnormal growth of cells. This uncontrolled, abnormal growth is beyond the natural boundaries of normal cell growth, which can then metastasize to adjoining or distant sites of the body and/or to the organs. Cancer is the second most leading cause of mortality and has resulted in 9.8 million deaths in 2018 alone. Efforts to explore newer anticancer drugs have significantly increased in recent years. Appropriate preclinical experimental screening models can help us apprehend the pathogenesis, complications, and testing of various therapeutic agents. Both in-vitro, as well as in-vivo models are available for the screening of compounds. A preclinical screening model should have a high sensitivity and reproducibility. This review summarizes some conventional as well as newer experimental screening models used for preclinical screening of test compounds for the treatment of cancer.
C. Singh, S. Khan, F. Bamne and I. Ansari *
Department of Pharmacology, Oriental College of Pharmacy, Navi Mumbai, Maharashtra, India.
03 April 2020
17 August 2020
12 September 2020
01 April 2021